House Panel Looks for the Next Steps After JOBS Act
By Mari Serebrov
Thursday, July 11, 2013
Many of the small biotechs that went public thanks to the Jumpstart Our Business Startups (JOBS) Act "could be left to die on the vine" unless Congress takes additional steps to help emerging growth companies (EGCs) fully access the market, a House subcommittee was told this week.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.